It’s a great idea to invest in us – and here’s why
- Poised for long-term growth; building on attractive mega trends in Life Science, Healthcare and Electronics
- Resilient and high-quality cashflow profile; reliable cash generation leveraging multi-industry set up
- Strong M&A track record enhanced by rapid deleveraging
- Bringing innovation faster to patients and customers, contributing to their sustainability efforts
Related News
View All News-
Press Releases
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in SLE at EULAR ...
Company presents phase 2 data of enpatoran in systemic lupus erythematosus, highlighting improved efficacy in patients with active skin manifestations
2025/06/12
-
Press Releases
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy ...
Merck KGaA, Darmstadt, Germany, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib in TGCT.
2025/05/28
-
Press Releases
Merck KGaA, Darmstadt, Germany, Showcases Innovation in Advanced Cancers and ...
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
2025/05/22
Share Price
Check Share PriceShare Price
Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.
Financials
Read MoreFinancials
Our Financial Reporting Center offers you the opportunity to select from financial data on an annual or quarterly basis.